Actively Recruiting
Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
Led by The University of Hong Kong · Updated on 2024-12-16
100
Participants Needed
1
Research Sites
865 weeks
Total Duration
On this page
Sponsors
T
The University of Hong Kong
Lead Sponsor
T
The Hong Kong Society of Nephrology
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers investigated include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.
CONDITIONS
Official Title
Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation
- Willing to give informed consent
You will not qualify if you...
- Patients with co-existing renal diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Queen Mary Hospital, Hong Kong
Hong Kong, Hong Kong
Actively Recruiting
Research Team
D
Desmond Yap, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here